Mohammad saeed Kahrizi

Dr. Mohammad saeed Kahrizi

Alborz University of Medical Sciences, Karaj, Alborz, Iran
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2022 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
HSHourieh Sadrekarimi
Hourieh Sadrekarimi
ZGZhanna Gardanova
Zhanna Gardanova
MBMorteza Bakhshesh
Morteza Bakhshesh
FEFarnoosh Ebrahimzadeh
Farnoosh Ebrahimzadeh
AYAmirhossein Fakhre Yaseri
Amirhossein Fakhre Yaseri
MKMohammad saeed Kahrizi
Mohammad saeed Kahrizi
In recent years, there has been a greater emphasis on the impact of microbial populations inhabiting the gastrointestinal tract on human health and disease. According to the involvement of microbiota in modulating physiological processes (such as immune system development, vitamins synthesis, pathogen displacement, and nutrient uptake), any alteration in its composition and diversity (i.e., dysbiosis) has been linked to a variety of pathologies, including cancer. In this bidirectional relationship, colonization with various bacterial species is correlated with a reduced or elevated risk of certain cancers. Notably, the gut microflora could potentially play a direct or indirect role in tumor initiation and progression by inducing chronic inflammation and producing toxins and metabolites. Therefore, identifying the bacterial species involved and their mechanism of action could be beneficial in preventing the onset of tumors or controlling their advancement. Likewise, the microbial community affects anti-cancer approaches’ therapeutic potential and adverse effects (such as immunotherapy and chemotherapy). Hence, their efficiency should be evaluated in the context of the microbiome, underlining the importance of personalized medicine. In this review, we summarized the evidence revealing the microbiota's involvement in cancer and its mechanism. We also delineated how microbiota could predict colon carcinoma development or response to current treatments to improve clinical outcomes.

7 June 2023 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
MKMohammad saeed Kahrizi
Mohammad saeed Kahrizi
EMElnaz Mousavi
Elnaz Mousavi
AKArmin Khosravi
Armin Khosravi
SRSara Rahnama
Sara Rahnama
ASAli Salehi
Ali Salehi
SJSamira Jamali
Samira Jamali
Mesenchymal stem/stromal cells (MSCs)‐based therapy brings the reassuring capability to regenerative medicine through their self‐renewal and multilineage potency. Also, they secret a diversity of mediators, which are complicated in moderation of deregulated immune responses, and yielding angiogenesis in vivo. Nonetheless, MSCs may lose biological performance after procurement and prolonged expansion in vitro. Also, following transplantation and migration to target tissue, they encounter a harsh milieu accompanied by death signals because of the lack of proper tensegrity structure between the cells and matrix. Accordingly, pre-conditioning of MSCs is strongly suggested to upgrade their performances in vivo, leading to more favored transplantation efficacy in regenerative medicine. Indeed, MSCs ex vivo pre-conditioning by hypoxia, inflammatory stimulus, or other factors/conditions may stimulate their survival, proliferation, migration, exosome secretion, and pro-angiogenic and anti-inflammatory characteristics in vivo. In this review, we deliver an overview of the pre-conditioning methods that are considered a strategy for improving the therapeutic efficacy of MSCs in organ failures, in particular, renal, heart, lung, and liver.

24 September 2022 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
AKAli Keshavarz
Ali Keshavarz
ASAli Salehi
Ali Salehi
SKSetareh Khosravi
Setareh Khosravi
YSYasaman Shariati
Yasaman Shariati
NNNavid Nasrabadi
Navid Nasrabadi
FFFarnoush Fotovat
Farnoush Fotovat
Advancements in adoptive cell therapy over the last four decades have revealed various new therapeutic strategies, such as chimeric antigen receptors (CARs), which are dedicated immune cells that are engineered and administered to eliminate cancer cells. In this context, CAR T-cells have shown significant promise in the treatment of hematological malignancies. However, many obstacles limit the efficacy of CAR T-cell therapy in both solid tumors and hematological malignancies. Consequently, CAR-NK and CAR-M cell therapies have recently emerged as novel therapeutic options for addressing the challenges associated with CAR T-cell therapies. Currently, many CAR immune cell trials are underway in various human malignancies around the world to improve antitumor activity and reduce the toxicity of CAR immune cell therapy. This review will describe the comprehensive literature of recent findings on CAR immune cell therapy in a wide range of human malignancies, as well as the challenges that have emerged in recent years.

12 December 2022 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
MJMohammadsaleh Jahangir
Mohammadsaleh Jahangir
OYOmid Yazdani
Omid Yazdani
MKMohammad saeed Kahrizi
Mohammad saeed Kahrizi
SSSara Soltanzadeh
Sara Soltanzadeh
HJHamidreza Javididashtbayaz
Hamidreza Javididashtbayaz
RERomina Esbati
Romina Esbati
Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade therapy has become a game-changing therapeutic approach revolutionizing the treatment setting of human malignancies, such as renal cell carcinoma (RCC). Despite the remarkable clinical activity of anti-PD-1 or anti-PD-L1 monoclonal antibodies, only a small portion of patients exhibit a positive response to PD-1/PD-L1 blockade therapy, and the primary or acquired resistance might ultimately favor cancer development in patients with clinical responses. In light of this, recent reports have signified that the addition of other therapeutic modalities to PD-1/PD-L1 blockade therapy might improve clinical responses in advanced RCC patients. Until, combination therapy with PD-1/PD-L1 blockade therapy plus cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitor (ipilimumab) or various vascular endothelial growth factor receptors (VEGFRs) inhibitors axitinib, such as axitinib and cabozantinib, has been approved by the United States Food and Drug Administration (FDA) as first-line treatment for metastatic RCC. In the present review, we have focused on the therapeutic benefits of the PD-1/PD-L1 blockade therapy as a single agent or in combination with other conventional or innovative targeted therapies in RCC patients. We also offer a glimpse into the well-determined prognostic factor associated with the clinical response of RCC patients to PD-1/PD-L1 blockade therapy.

27 January 2025 in Heliyon
Verified
Journal Article
Open access
SKSeyede Sara Pakdaman Kolour
Seyede Sara Pakdaman Kolour
SNSaeide Nematollahi
Saeide Nematollahi
MDMasoud Dehbozorgi
Masoud Dehbozorgi
FFFarnaz Fattahi
Farnaz Fattahi
FMFatemeh Movahed
Fatemeh Movahed
BHBahareh Salmanian Hajiagha
Bahareh Salmanian Hajiagha
The primary cause of pain and disability in the world is osteoarthritis (OA), a common joint disease characterized by the primary pathological alteration in articular cartilage deterioration. The general outcome of treatment is not acceptable despite current interventions. Therefore, joint replacement surgery is frequently needed by patients with severe OA. Mesenchymal stem cells (MSCs) have become a practical treatment choice for preclinical and clinical OA palliation in recent years, mainly due to their unique immunomodulatory attributes. Further, attractive candidates for cell-free therapy for OA are MSC-derived extracecellulr vesicles (EVs) that convey bioactive molecules of the original cells, such as microRNAs. These EVs have been shown to significantly influence the regulation of various physiological activities of cells in the joint cavity. Dysregulated miRNAs upregulate the synthesis of enzymes that degrade cartilage, downregulate the expression of components in the cartilage matrix, promote the production of proinflammatory cytokines, induce programmed cell death in chondrocytes, inhibit the process of autophagy in chondrocytes, and participate in pathways related to pain. MiRNAs are also found in extracellular membranous vesicles (EVs), such as exosomes, and play a role in intercellular communication in osteoarthritic joints. Thus, the biosynthesis, chemical makeup, and mechanism of action of miRNAs-enriched EVs in OA are all thoroughly covered in this review. We additionally discussed how miRNA-enriched MSC-EVs might be used therapeutically to change intercellular interaction in OA.

7 July 2022 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
ASAhmad Saburi
Ahmad Saburi
MKMohammad saeed Kahrizi
Mohammad saeed Kahrizi
NNNavid Naghsh
Navid Naghsh
HEHasti Etemadi
Hasti Etemadi
AIAhmet İlhan
Ahmet İlhan
GEGülinnaz Ercan
Gülinnaz Ercan
Ovarian cancer (OC), a frequent malignant tumor that affects women, is one of the leading causes of cancer-related death in this group of individuals. For the treatment of ovarian cancer, systemic chemotherapy with platinum-based drugs or taxanes is the first-line option. However, drug resistance developed over time during chemotherapy medications worsens the situation. Since uncertainty exists for the mechanism of chemotherapy resistance in ovarian cancer, there is a need to investigate and overcome this problem. miRNAs are engaged in various signaling pathways that contribute to the chemotherapeutic resistance of ovarian cancer. In the current study, we have tried to shed light on the mechanisms by which microRNAs contribute to the drug resistance of ovarian cancer and the use of some microRNAs to combat this chemoresistance, leading to the worse outcome of ovarian cancer patients treated with systemic chemotherapeutics.